Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Brief summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of repeated inhalative doses of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.
Interventions
DRUGBimosiamose
DRUGPlacebo
Sponsors
Revotar Biopharmaceuticals AG
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Able to produce sputum with normal sputum neutrophil levels at screening (\< 65% of non-epithelial cells). * Ozone responsive, defined as ≥ 20% relative increase in sputum neutrophils cell count after 3 h ozone challenge. * At screening FEV1 at least 80% of predicted.
Exclusion criteria
* Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during screening for all subjects. Smokers will be defined as any subject who reports of a recent tobacco use and/or who has a urine cotinine ≥ 500 ng/mL. * Significant illness within two weeks prior to dosing (e.g., infection). * Recent (within the last three years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
Countries
Germany
Outcome results
None listed